Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …

Interferon-A (IFN-A) is an effective agent in the treatment of chronic myelogenous leukemia
(CML). Hematologic remissions occur in the majority of patients with newly diagnosed …

Several prospective randomized studies have shown that the treatment of chronic myeloid
leukemia with interferon-(IFN-) prolongs the survival by comparison with conventional …

Between March 1988 and July 1990, 28 adults with chronic myelogenous leukaemia (CML)
were treated with a combination of recombinant human interferon (IFN) alpha‐2b sc (initial …

Objective: To determine the toxicity and efficacy of low-dose interferon-α therapy in inducing
remissions and prolonging survival in patients with chronic myeloid leukemia. Design …

Twenty-four patients with Philadelphia positive (Ph+) chronic myelogenous leukemia
including 12 who were previously untreated, received recombinant interferon alpha-2a …

Interferon-alfa (IFNα) became the first-line agent for the treatment of chronic myeloid
leukemia (CML) because it prolongs survival significantly compared to conventional …

A multicenter randomized study was conducted to compare the effect of interferon-alpha
(IFN-alpha) with that of busulfan in newly diagnosed patients with chronic myelogenous …

Purpose: 79 monitor treatment results and survival in chronic myeloid leukemia after
allogeneic bone marrow transplantation (alloBMT) and the introduction of interferon alpha …

Twenty‐seven consecutive patients with previously untreated, or minimally treated benign
phase Philadelphia‐chromosome‐positive, chronic myelogenous leukaemia (CML) were …